Document is current

Any future updates will be listed below

Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study

Crossref DOI link: https://doi.org/10.1038/s41391-025-01068-2

Published Online: 2025-12-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark